REQUEST A DEMO
Total
USD $0.00
Search more companies

Nougenetik Pharmaceuticals S.A.S. (Ecuador)

Main Activities: Marketing Research and Public Opinion Polling
Full name: Nougenetik Pharmaceuticals S.A.S. Profile Updated: August 02, 2023
Buy our report for this company USD 29.95 Most recent financial data: 2023 Available in: English & Spanish Download a sample report

Nougenetik Pharmaceuticals S.A.S. is a company in Ecuador, with a head office in Quito. It operates in the Marketing Research and Public Opinion Polling industry. It was incorporated on October 01, 2021. There are currently 4 (2022) people employed by Nougenetik Pharmaceuticals S.A.S.. The company’s latest financial report indicates a net sales revenue increase of 256.13% in 2023. Over the same period, its total assets grew by 90.63%. The enterprise’s net profit margin decreased by 25.66% in 2023.

Headquarters
Calle Francisco Ushina
Quito; Pichincha;

Contact Details: Purchase the Nougenetik Pharmaceuticals S.A.S. report to view the information.

Basic Information
Total Employees:
Purchase the Nougenetik Pharmaceuticals S.A.S. report to view the information.
Outstanding Shares:
Purchase the Nougenetik Pharmaceuticals S.A.S. report to view the information.
Registered Capital:
Purchase the Nougenetik Pharmaceuticals S.A.S. report to view the information.
Incorporation Date:
October 01, 2021
Key Executives
Purchase this report to view the information.
General Manager
Company Performance
Financial values in the chart are available after Nougenetik Pharmaceuticals S.A.S. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency USD. Absolute financial data is included in the purchased report.
Net sales revenue
256.13%
Total operating revenue
256.13%
Operating profit (EBIT)
8.88%
EBITDA
17.54%
Net Profit (Loss) for the Period
26.39%
Total assets
90.63%
Total equity
123.6%
Operating Profit Margin (ROS)
-48.34%
Net Profit Margin
-25.66%
Return on Equity (ROE)
-42.51%
Debt to Equity Ratio
-92.77%
Quick Ratio
0.14%
Cash Ratio
0.53%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?